NGeneBio Co., Ltd. (KOSDAQ:354200)

South Korea flag South Korea · Delayed Price · Currency is KRW
1,938.00
+95.00 (5.15%)
At close: Aug 8, 2025, 3:30 PM KST
-44.47%
Market Cap 48.62B
Revenue (ttm) 6.85B
Net Income (ttm) -12.20B
Shares Out 25.04M
EPS (ttm) -958.68
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 104,001
Average Volume 90,204
Open 1,845.00
Previous Close 1,843.00
Day's Range 1,837.00 - 1,939.00
52-Week Range 1,503.00 - 5,300.00
Beta 1.20
RSI 52.33
Earnings Date Aug 14, 2025

About NGeneBio

NGeneBio Co., Ltd. develops in vitro diagnostics companion diagnostics products and bioinformatics software. It offers BRCAaccuTest and BRCAaccuTest PLUS are reagent kits for breast and ovarian cancer, and hereditary breast and ovarian cancer syndrome; HEMEaccuTest, a clinical NGS kit for hematological malignancies, such as acute myeloid leukemia, acute lymphoid leukemia, myelodysplastic/myeloproliferative neoplasm, multiple myeloma, and lymphoma; SOLIDaccuTest, a genetic variants screening for solid tumors; HLAaccuTest, an in vitro diagnostic ... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2015
Employees 58
Stock Exchange KOSDAQ
Ticker Symbol 354200
Full Company Profile

Financial Performance

In 2024, NGeneBio's revenue was 5.69 billion, an increase of 30.80% compared to the previous year's 4.35 billion. Losses were -12.63 billion, -1.11% less than in 2023.

Financial Statements

News

There is no news available yet.